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ABSTRACT 
There is increased interest in the identification and analysis of gene 
fusions and chimeric RNA transcripts. While most recent efforts 
focused on the analysis of genomic and transcriptomic data, identi-
fication of novel peptides corresponding to such events in mass 
spectrometry-based proteomic datasets would provide complemen-
tary, protein-level evidence. The process of identifying fusion pro-
teins from mass spectrometry data is inherently difficult because 
such events are rare. It is also complicated due to large amount of 
spectra collected and the explosion in the number of candidate 
peptide sequences that need to be considered, which makes ex-
haustive search for all possible fusion partner proteins impractical. 
In this work, we present a sequence tag based fusion protein identi-
fication algorithm, FIT, that combines the virtue of both de novo 
sequence tag retrieval and peptide-spectrum matching for identifi-
cation of fusion proteins. Results on simulated datasets show high 
sensitivity and low false positive rates for fusion protein identifica-
tion by the FIT algorithm.  
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1 INTRODUCTION  
Fusion genes are formed through the rearrangement of two or more 
genes, which originally coded for separate proteins. Since fusion 
genes are often correlated with tumor biomarkers in cancer gene 
architecture 1,2, identification of fusion genes significantly contrib-
utes to the understanding of cancer progression. Most efforts natu-
rally focused on the identification of gene fusions and chimeric 
transcripts using genomics  data  3,4,5-7. In particular, multiple bio-
informatics tools for detection of chimeric transcripts from RNA-
Seq data have been recently described 8-11.  
Identification of fusion (or chimeric) proteins, i.e. protein-level 
products resulting from gene fusions and other types of chimeric 
transcripts from tandem mass spectrometry (MS/MS) data could 
serve as an alternative or supplementary method for detection of 
such events 12. A fusion protein is represented by Pi-p||Pj-s, in which 
Pi-p and Pj-s are prefix and suffix of protein Pi and Pj, respectively. 
Protein Pi and Pj are the protein products of two corresponding 
genes, and they are referred to as the “fusion partner proteins”. 
Each pair of fusion partner proteins corresponds to a fusion event, 
and the position in fusion protein where the two proteins “fuse” is 
referred to as the protein fusion site (breakpoint). The peptide that 
straddles the fusion site is referred to as a fusion (or chimeric) 
peptide. From proteomic experiment point of view, MS/MS da-
tasets acquired on biological samples containing fusion proteins 
may contain spectra representing fusion peptides. Therefore, com-
putational analysis of MS/MS datasets could lead to the identifica-
tion of fusion peptides and their corresponding fusion proteins.  
Many fusion proteins are already known, and more could be 
identified with confidence from e.g. RNA-Seq data when both 
RNA-Seq and MS/MS data are available for the same biological 
system. These known or predicted fusion peptide sequences can be 
added to the protein sequences database, and MS/MS spectra can 
then be searched against this protein database in a convention 
way13. However, the identification of truly novel fusion peptides 
from MS/MS data alone is difficult and so far has been attempted 
in only several works. The first, targeted approach 12 is based on de 
novo algorithm to identify peptide sequences, followed by align-
ment of these peptides against a limited set of protein sequences. In 
this work, the abundance of the fusion protein in the sample was 
increased via immunoprecipitation (IP) with an antibody against 
one of the fusion protein partners, followed by MS analysis (IP-
MS). Furthermore, multiple proteases were used to digest proteins 
to generate peptides overlapping the same fusion site, thus increas-
ing the confidence in the identification. The computational method 
used in this work assumed that at least one of the fusion partners is 
known a priori, and it cannot be effectively extended to less re-
strictive situations. The second approach is global in that it search-
es for all possible fusion sites. In this method, based on spectrum 
alignment14,15, fragments of protein sequences are transformed into 
theoretical spectra. The experimental MS/MS spectra are aligned 
against theoretical spectra of every possible combination of frag-
ments in the protein database. This method essentially performs an 
unrestricted search of all possible candidate fusion peptides (i.e. 
without restricting the analysis to any specific subset of proteins or 
spectra). As such it is computationally expensive and also may 
result in a high rate of false positive fusion peptide identifications. 
In this paper, we proposed a new algorithm, FIT, for sequence 
tag based fusion protein identification. FIT is designed to provide a 
solution that bridges the targeted and global approaches described 
above. It implements a protein sequence filtration step that restricts 
the fusion peptide search space by requiring that at least one of the 
candidate fusion partners is identified in the sample with high con-
fidence by known (i.e. non-fusion) peptides. This assumption re-
flects our expectation that fusion peptide identification would be 
most successful in the case of experiments that enrich the abun-
dance of otherwise low abundant fusion proteins (e.g. in IP-MS 
experiments in which the fusion protein is the bait protein or one of 
the interacting partners of the bait). Furthermore, MS/MS spectra 
are also filtered to keep only spectra that cannot be assigned with 
confidence to known protein sequences. Another key feature of 
FIT algorithm is the selection of candidate fusion partner proteins 
using sequence tags extracted from the spectra 16-20. In FIT, a set of 
tags are generated for each of the unassigned spectra, and then 
aligned to candidate proteins. A pair of candidate fusion partner 
proteins is selected only when a pair of tags from a single spectrum 
maps to these two proteins. Then FIT scores candidate fusion pep-
tides via full spectrum-peptide matching. 
The advantage of the proposed method is that fusion protein 
identifications are based on only a small subset of proteins and a 
small subset of all spectra. Using sequence tags for candidate fu-
sion peptide retrieval reduces the computational time and increases 
the sensitivity of peptide identification. Sequence tags generated 
from spectra are more reliable than de novo sequencing results, and 
the alignment of tags to protein sequences is followed up by con-
ventional spectrum-peptide matching. Therefore, FIT combines the 
virtue of both de novo tag retrieval and peptide-spectrum matching.  
2 METHODS 
2.1 Experiment data 
The primary goal of this work is to introduce the new method and 
to evaluate its performance. The evaluation of the method with 
respect to its ability to find novel fusion peptides in biological 
context is not feasible without substantial work to experimentally 
validate novel predictions. Thus, the performance of the algorithm 
is tested here using simulated experiments based on real MS/MS 
spectra and simulated fusion events. A similar strategy was used 
in12.  
  MS/MS spectra were taken from a publicly available Human T 
Leukemic Cells dataset 21, the first replicate of Whole Cell Lysate 
(WCL) fraction experiment. The spectral dataset used here con-
tained a total of 269,371 MS/MS spectra. The spectra were 
searched by X! TANDEM 22 (with k-score 23) against the Swis-
sProt database 24 (Release 57.10, appended with reversed protein 
sequences of equal size as decoys), or against the modified data-
base (referred to as “fusion database” below) created as described 
below. The search parameters in all searches were: 2.0 Da parent 
mass tolerance, 0.8 Da fragment monoisotopic mass tolerance, and 
allowing tryptic peptide only. Two modifications were considered 
as variable modifications: Met oxidation and N-terminal acetyla-
tion. Peptide to spectrum matches were analyzed using Pep-
tideProphet and ProteinProphet 25, which posterior probabilities to 
peptide and protein identifications, respectively (described in more 
detail below).  
2.2 Simulated fusion database construction 
To create the simulated fusion database, we first selected top 200 
proteins with highest abundances and with ProteinProphet proba-
bilities (> 0.9) based on the initial search of the experimental 
MS/MS data against the regular SwissProt database (see Experi-
mental Data). These proteins were considered as “fusion proteins” 
(ground truth) to be identified by searching MS/MS spectra against 
this simulated fusion protein database. Second, 200 unique pep-
tides, each being selected from one of the 200 proteins, were ex-
tracted, and preference was given to peptides located near the mid-
dle of the protein sequences. These peptides represent the “fusion 
peptides” to be identified. Third, each of the 200 fusion proteins 
was broken at a breakpoint (referred to as “fusion sites”). The fu-
sion site was set either at the middle of the corresponding fusion 
peptide, or shifted with respect to the middle of the peptide by one 
or more amino acids in either direction. The fusion protein was 
then translocated with a fragment of another protein randomly 
selected from the list of all identified proteins (Figure 1). This 
procedure reflects in part the real situation in which many genes 
involved in fusion recombine with different partners 26. Each pair 
of proteins thus constructed is referred to as a pair of “fusion part-
ner proteins”. Then the proteins that are used to construct these 
fusion partner proteins are removed from the database, and the new 
fusion partner proteins are inserted (Figure 1).  
 
 
Figure 1. An illustration of creating one pair of fusion partner proteins based on 
proteins Pi and Pj. Shaded fractions represent the fusion peptide for this fusion event. 
Both Pi (one of the top 200 proteins based on abundance) and Pj (randomly selected 
among all identified proteins) are extracted from protein database, translocated, and 
the resulting two proteins are inserted back in the protein database. 
 
2.3 The FIT algorithm 
FIT algorithm implements the following major steps: filtering of 
protein sequences and MS/MS spectra; selection of fusion partner 
proteins by sequence tagging; scoring of MS/MS spectra against 
candidate fusion peptides. 
 
2.2.1 Phase I, Restrict the search space for fusion partner pro-
teins and protein fusion site In the initial database search, all spec-
tra (referred to as {S}) are searched by X! TANDEM 22 against 
protein sequences database (referred to as {P}) for peptide identifi-
cation. Then PeptideProphet 27 (a tool to automatically validate 
peptide assignments to MS/MS spectra made by database search, a 
part of the TPP suite 28) is used to assign a probability to each of 
the peptide to spectrum matches. ProteinProphet 25 then performs 
protein level inference and computes a protein probability.  
Selected peptides (with a high PeptideProphet probability) are 
mapped to protein sequences, and the protein coverage is comput-
ed as the proportion of the sequence covered by the identified pep-
tides. The set of proteins {Pselected} selected as fusion protein can-
didates can be represented as:  
 
{Pselected} = {P | ProteinProphet(P)>0.9 & coverage(P)>0.5} (1) 
 
To restrict the number of proteins to be searched for computa-
tional efficiency, and more importantly to ensure reliable (low 
error rate) identification of fusion peptides, it is required that at 
least one of the two candidate fusion partner proteins is in the se-
lected set described above. Additionally, it is assumed that there is 
no “known” peptide identified in the dataset from either one of the 
fusion partner proteins that overlaps with the fusion site. Further-
more, only fragments that do not have peptide alignments could 
contain possible protein fusion site (in general, these assumptions 
may not always be true; the cells can express both protein forms, 
i.e. the canonical protein and the chimera form).  
2.2.2 Phase II， Restricting the number of candidate spectra 
To restrict the number of candidate spectra that may identify fusion 
peptides, spectra that can be assigned to peptides from known pro-
teins with high confidence (with a probability threshold corre-
sponding to false discovery rate, FDR, below 0.05) are filtered out.  
Then, a spectrum quality score (SQS) 29, which is a score that takes 
into consideration multiple features reflecting MS/MS spectrum 
quality (total number of peaks, signal to noise level, etc.), is com-
puted for each spectrum. Spectra with SQS scores above 1.0 are 
considered high quality spectra29. Those spectra that have low 
PeptideProphet probability (below the threshold) and SQS score 
above 1.0 are considered unassigned high quality spectra. A fusion 
peptide is more likely to be identified from this selected set of 
spectra, denoted as {Sselected}: 
 
{Sselected} = {S | PeptideProphet(S)<threshold & SQS(S)>1.0) (2) 
 
2.2.3 Phase III, Selection of candidate fusion proteins by tag 
Since a fusion peptide straddles the protein fusion site, it should 
have its prefix matching one protein, and its suffix matching an-
other protein. Two proteins, Pi and Pj are selected as putative fu-
sion partner proteins when there is a spectrum S (from the selected 
set, see E. 2) from which we can generate two tags Ti and Tj, with 
Ti (and its prefix mass) matching Pi and Tj (and its suffix mass) 
matching Pj. An illustration of this tag mapping process is shown 
in Figure 2. The mapping of sequence tags as well as prefix and 
suffix masses are based on the PepLine 30 software, which could 
map peptide sequence tags (PST, consisting of tag sequence and its 
prefix or suffix masses) from the spectrum onto protein sequences.  
  
Figure 2. An illustration of putative fusion partner protein selection based on 
extracted sequence tags. Solid boxes indicate assigned peptides, Thick bars indicate 
tag sequences and dashed boxes indicate tags that include prefix and suffix masses. 
 
2.2.4 Phase IV, Identification of fusion protein The candidate 
fusion peptides nominated as described above are scored via direct 
spectrum-peptide comparison. The dot product score is computed 
using X! Tandem for each spectrum S and its corresponding candi-
date fusion peptide Pi-p||Pj-s. Good matches are expected to have a 
large dot product  (generally > 300); as a set, the list of accepted 
fusion peptides should have a small FDR (e.g. < 0.01) 31. At this 
stage, experiment specific properties such as the specificity of the 
proteolytic enzyme used to digest proteins can be used to eliminate 
candidate peptides containing missed cleavages or not conforming 
to the enzymatic cleavage rules at the N- or C-terminus. Addition-
ally, fusion peptides could be required to be identified from multi-
ple MS/MS spectra. 
3 RESULTS AND DISCUSSIONS 
The primary goal of this work is to introduce the new method and 
to evaluate its performance. The evaluation of the method with 
respect to its ability to find novel fusion peptides in biological 
context is not feasible without substantial work to experimentally 
validate novel predictions. Thus, the performance of the algorithm 
is tested here using simulated experiments based on real MS/MS 
spectra and simulated fusion events. A similar strategy was used 
in12.  
3.1 Experiment data and simulated fusion database  
  MS/MS spectra were taken from a publicly available Human T 
Leukemic Cells dataset 21 (see Methods for detail). The spectral 
dataset, containing 269,371 MS/MS spectra, was first searched by 
X! TANDEM 22 (with k-score 23) against the SwissProt database 24 
(Release 57.10, appended with reversed protein sequences of equal 
size as decoys).  Peptide to spectrum matches were analyzed using 
PeptideProphet and ProteinProphet 25, leading to the identification 
of 1,936 SwissProt protein entries with high ProteinProphet proba-
bilities (decoy-estimated FDR of ~ 0.01). Among the 224,614 
spectra that were initially unassigned, 7,098 spectra are of high 
quality (SQS > 1.0).  
  The simulated fusion protein database was created as follows (see 
Method for details). The protein abundance of each of the identi-
fied protein was estimated using spectrum counts 32. Proteins were 
then sorted by their abundance, and the top 200 proteins with high-
est abundances were selected as fusion proteins. Then, 200 unique 
“fusion peptides” were selected from these proteins, corresponding 
to a total of 521 spectra (referred to as “positive spectra dataset”) – 
a small fraction compared to the total of 269,371 spectra in this 
dataset. Each of these “fusion proteins” were broken at a break-
point (set at the middle of the corresponding fusion peptide), and 
translocated with another protein (not necessarily identified with 
high probability). This process resulted in 180 randomly selected 
proteins to be translocated with 200 selected high abundance pro-
teins to construct “fusion partner proteins”. The original proteins 
that were used to construct these “fusion partner proteins” were 
removed from the protein database, and the “fusion partner pro-
teins” were inserted in it instead. The fusion protein database thus 
constructed contained 20,402 proteins, in which 20,042 proteins 
are identical to the ones in the original protein database. By this 
construction, positive spectra do not have the corresponding pep-
tides in simulated fusion protein database, but they could be identi-
fied as fusion peptides by FIT method.  
  It is acknowledged that the simulated fusion database generation 
procedure described above (and also in the FIT algorithm) makes a 
number of simplifying assumptions regarding the fusion protein 
identification problem. Nevertheless, the key assumptions are not 
without the merit. Most importantly, it is assumed that at least one 
of the proteins involved in fusion is detected with high sequence 
coverage. As discussed in the Introduction, we believe that it is 
most realistic to search for fusion peptides in datasets generated in 
experiments in which fusion proteins are enriched, such as IP-MS 
experiments targeting a protein (and its interacting partners) from a 
particular (often cancer-related) pathway of interest. The computa-
tional tests performed also reflect another major difficulty, the fact 
that only a tiny fraction of all acquired MS/MS spectra in the da-
taset correspond to fusion peptides.  
 
3.2 Candidate fusion protein selection and identifica-
tion 
3.2.1  Phase I, Filtration of proteins  
All spectra from WCL dataset were re-searched against the simu-
lated fusion protein database in the same way as in the original 
search. Based on this database search, 2,458 protein entries were 
identified with high ProteinProphet probabilities (> 0.9; corre-
sponding FDR of 0.009). Additionally, it is noticed that out of the 
originally identifiable 1,936 proteins, 1,754 (90.6%) untranslocated 
proteins would still be identified from searching the simulated 
fusion protein database (Table 1). This indicates that the construc-
tion of the simulated fusion protein database does not significantly 
change the set of proteins that could be identified with high Pro-
teinProphet probability. 
  We first analyzed the effect of protein filtration on fusion protein 
selection. There are two measurements for this analysis: the pro-
portion of fusion partner proteins that can generate correct fusion 
partner protein pairs (% of fusion partner proteins) after filtration, 
and the number of fusion events that could be identified after filtra-
tion (number of fusion proteins). We have first analyzed the effect 
of applying different ProteinProphet probability threshold on one 
or both of the fusion partner proteins. Applying ProteinProphet 
probability threshold of 0.9 on one of the fusion partner proteins, 
95% of fusion partner proteins that pass the filtration could form 
fusion partner protein pairs, and 90% (180/200) of fusion proteins 
could be still identified after filtration. When this ProteinProphet 
probability threshold was applied to both of the fusion partner 
proteins, there were 176 and 173 fusion partner proteins that con-
tained the prefix and suffix of correct fusion proteins and passed 
the filtration; 84% (167/200) of fusion proteins could be identified 
from these fusion partner proteins (Table 1). In other words, in this 
dataset requiring that both of the fusion partner proteins pass the 
probability threshold of 0.9 did not significantly reduce the number 
of identifiable fusion protein, whereas the number of possible 
combinations of fusion partner proteins was reduced drastically.   
Another protein filtration step that we implemented is based on 
requiring certain minimum protein sequence coverage by identified 
peptides. Based on fusion partner proteins that passed the Pro-
teinProphet probability threshold (0.9), it was observed that as the 
required protein coverage increased, the number of true fusion 
proteins that could be identified was consistently decreasing (Fig-
ure 3). At the same time, the total number of candidate fusion part-
ner pairs was decreasing as well. As a tradeoff, we selected the 
protein coverage threshold of 0.5 (required for at least one of the 
two fusion partner candidates) as a filter. It should be noted that 
the protein filters described above are likely to be dataset specific, 
and may have to be adjusted for different dataset.   
 
 
 
Figure 3. The effect of protein coverage threshold on the filtration of fusion 
proteins.  Results correspond to requiring that at least one of the two fusion partner 
proteins pass a specific protein coverage threshold (in addition to the ProteinProphet 
probability threshold of 0.9 applied on both fusion partner proteins). “% of fusion 
partner proteins” is computed by dividing the number of fusion partner proteins after 
filtration that can generate correct fusion partner protein pairs by the total number of 
fusion partner proteins after filtration. 
 
3.2.2  Phase II, Filtration of spectra  
Apart from protein filtration, MS/MS spectra are also filtered. 
Based on PeptideProphet probability (> 0.7 are considered as as-
signed; FDR = 0.03) and spectrum quality score (SQS > 1.0 as 
high quality) assigned to each of the spectra, there were 231,608 
unassigned spectra, of which 8,712 were of high quality. These 
numbers are quite similar to the results of searching the original 
protein database. From the results of this database search, it was 
also observed that out of the 521 spectra in positive dataset 
(ground truth), 6 are charge 1 spectra, and 20 were assigned to 
peptides in the fusion protein database (i.e., there was another, 
likely homologous, protein in the database containing the same 
sequence). The remaining 495 spectra were unassigned spectra, 
corresponding to 178 fusion proteins, out of which 167 fusion 
proteins had both fusion partner proteins identified with Pro-
teinProphet probability > 0.9 (Table 1). 391 out of these 495 spec-
tra were of high quality, corresponding to 165 fusion proteins after 
protein filtration.  
  
3.2.3 Phase III, Selecting candidate fusion proteins by tags  
As the next step, we have analyzed the effect of fusion protein 
selection from fusion partner proteins using sequence tags. Previ-
ous studies have shown that first, for the majority of spectra, 
among top 100 tags, there are at least 2 length-2 tags that are cor-
rect; and among top 200 tags, there are at least 2 length-3 tags that 
are correct. Second, most of the tags are distributed near the center 
of the peptide sequences 33. Therefore, in this study, we generated 
top 100 length-2 and top 200 length-3 tags for each of the spectra. 
When mapping tags on fusion partner proteins, it is discovered that 
based on length-3 tags, there are only 163 spectra (out of 495 spec-
tra) from positive dataset for which tags can be mapped to both 
fusion partner proteins. Based on length-2 tags, there are 227 spec-
tra (out of 495 spectra) from positive datasets for which tags can be 
mapped to both prefix and suffix of the fusion proteins (Table 1). 
Thus, using length-2 tags allows selection of a higher percentage 
of true fusion peptides than length-3 tags.  
   The tag-based selection of fusion protein candidates resulted in 
approximately 30% loss in the number of possible fusion protein 
identifications (in contrast, the protein filtration step resulted in the 
loss of  37 fusion proteins, or less than 20%), see Table 1. We thus 
further investigated the reason for the 30% loss at the sequence 
tag-based filtering stage. We found that when the fusion breakpoint 
is in the middle of the fusion peptide sequence (as we implemented 
as a part of our procedure for creating the simulated fusion protein 
database), many of the extracted sequence tags cannot be mapped 
to either prefix or suffix of the fusion peptide (i.e., there is no pair 
of tags that could map to the prefix and suffix of the corresponding 
protein fusion candidate sequences).  
To further assess the effect of breakpoint position on candidate 
fusion protein selection, the analysis was repeated using different 
sets of fusion partner proteins with breakpoints shifted (either left 
or right) with respect to the middle of the fusion peptide sequence 
(keeping others settings the same). Results based on different 
breakpoints (defined as the offset from the middle of the peptide) 
of the fusion proteins are shown in Figure 4. It is interesting to note 
that offset of 1 amino acid would yield largest number of fusion 
event detection. Specifically, based on length-3 tags, 294 spectra in 
positive dataset can be assigned to correct fusion proteins if the 
fusion partner proteins are created with breakpoint offset middle of 
peptide by 1 amino acid. Based on length-2 tags, 471 spectra in 
positive dataset can be assigned to correct fusion proteins if the 
fusion partner proteins are created with breakpoint offset middle of 
peptide by 1 amino acid. The main reason for significant increase 
of the number of spectra that could be retrieved by tags is that the 
middle part of the peptide is usually fragmented more completely 
than other parts of the peptide 33, and therefore most of tags from 
spectra correspond to the middle part of the peptide. If breakpoint 
is set at the middle, then some of the tags are unmappable on either 
prefix or suffix of fusion peptide. Shifting ≥ 1 amino acids from 
the middle could attribute these tags to either prefix or suffix of the 
fusion peptide, and therefore increase the number of spectra that 
could be selected by tags. Based on these spectra and 167 fusion 
proteins that could be identified after protein filtration, shifting 
breakpoint would yield sensitivity (#true positive / (#true positive 
+ #false negative)) of 73.7% (123/167) based on length-3 tags, and 
sensitivity of 93.4% (156/167) based on length-2 tags for fusion 
protein selection. The overall sensitivity of 61.5% (123/200) and 
78.0% (156/200) could be achieved based on length-3 tags and 
length-2 tags by the FIT algorithm, respectively (Table 1). 
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Figure 4. The number of spectra in positive dataset that could be selected by tags, 
categorized by the offset of breakpoint from middle of the fusion peptide. Shift 
values indicate the absolute shift values from the middle. Results are based on filtered 
fusion partner proteins for (a) length-3 tags and (b) length-2 tags. 
Table 1. The number of spectra and proteins after each filtration and scoring step. 
After protein filtering, only results based on filtering both of the fusion partner pro-
teins are used, and in peptide-spectrum scoring, only results based on length-2 tags are 
shown. HQ: Results based on using high quality (SQS>1) spectra only. 
 Original After pro-
tein filtering 
After 
spectra 
filtering  
(FDR < 
0.05) 
After fusion part-
ner protein match-
ing  by tags 
After peptide-
spectrum-match 
scoring (FDR < 
0.01) 
# of all spectra 269,371 - 231,608  
(HQ: 8,712) 
Length-2 tag: 516 
Length-3 tag: 451 
- 
# of all proteins 20,402 2,458 - - - 
# of spectra for 
fusion proteins  
521 - 495  
(HQ: 391) 
Length-2 tag: 471 
(Breakpoint at 
middle: 227) 
Length-3 tag: 294 
(Breakpoint at 
middle: 163) 
Length-2 tag: 295 
(HQ: 370) 
# of fusion 
proteins identi-
fiable 
200 167 
(Filtering one 
partner: 180) 
167 
(HQ: 165) 
Length-2 tag: 156 
Length-3 tag: 123 
Length-2 tag: 125 
(HQ: 146) 
 
3.2.4 Phase IV, Scoring of fusion proteins  
After fusion partner protein matching using extracted sequence 
tags, the number of candidate fusion proteins and candidate spectra 
to be considered has been drastically reduced. However, there are 
still a number of candidate fusion peptides presented (354 in total), 
of which a substantial proportion (198/354, or 56.0%) are false 
positives. Therefore, fusion peptides are further scored via the 
cross correlation analysis of the full experimental and theoretical 
peptide spectra. We have performed this scoring by searching {Sse-
lected} using X! Tandem (enzymatic cleavage rules considered in 
the search) against a protein database constructed as follows. We 
have collected all candidate fusion peptides (354 candidate pep-
tides in total, of which 156 correspond to ground truth), and ap-
pended this collection of peptides to the list of 2,458 proteins iden-
tified with ProteinProphet probabilities > 0.9 in the earlier X! Tan-
dem search against the simulated fusion protein database.        
   Two spectral sets were searched against this new database. One 
spectral set contains all initially unassigned spectra (a superset of 
{Sselected}) that are selected by length-2 tags (including 471 spectra 
in positive dataset), and another spectra dataset contains high 
quality unassigned spectra ({Sselected}) that are selected by length-2 
tags (including 375 spectra in positive dataset). All matches be-
tween spectra in the positive dataset and their corresponding pep-
tides were considered correct. Incorrect matches included matches 
of spectra in the positive dataset to peptides that are not their re-
spective fusion peptides, as well as matches of spectra not in the 
positive datasets to fusion peptides. The peptide-spectrum matches 
were sorted by their X! Tandem dot product scores, and the FDR 
was computed based on the number of correct and incorrect 
matches passing a particular score threshold. Results show that the 
majority of fusion peptides could be identified with very small 
FDR (Figure 5). Based on high quality unassigned spectra, 146 
true fusion peptides (out of 156) could be identified at FDR < 0.01. 
On the other hand, based on all initially unassigned spectra, only 
125 fusion peptides could be identified at the same FDR (Table 1). 
Thus, searching high quality unassigned spectra (as compared to 
all spectra) improve the accuracy of fusion peptide identification.  
 
 
Figure 5. The correlation of the number of correct fusion event identified and the 
FDR for fusion event identification. The fusion event identifications are performed 
based on two spectra datasets: one containing all unassigned spectra, another contain-
ing high quality unassigned spectra. 
 
We have also analyzed the relationship of the number of spectra 
with the likelihood of the fusion peptide identification. In the posi-
tive dataset, there were cases of multiple MS/MS spectra corre-
spond to the same peptide (521 spectra for 200 unique fusion pep-
tides). We have computed the number of spectra per unique fusion 
peptide, and analyzed its relationship with the identification rate of 
the fusion event. The identification ratio is defined here as the 
number of fusion peptide identified by FIT, over the total number 
of selected fusion peptides. Figure 6 shows that the identification 
ratio increases with the increasing number of spectra per peptide. 
For example, for fusion peptide identification based on length-3 
tags, with the number of spectra per peptide equal to 1, the identi-
fication ratio is around 40%. When the number of spectra per pep-
tide is greater than 1, the identification ratio is higher than 60%. 
This shows that, as expected, the sensitivity of fusion event identi-
fication is positively correlated with the number of spectra per 
peptide. 
 
 
 
Figure 6. The identification ratio of fusion events against the number of spectra 
per fusion peptide. X-axis represents the number of spectra per peptide threshold for 
fusion peptide, and y-axis represents identification ratio. Results are based on filtered 
fusion partner proteins and length-2 tags. 
 
4 CONCLUSIONS 
Fusion protein identification from MS/MS data is a potentially 
valuable strategy for detection of such events at the protein level. 
However, current large-scale proteomic experiments generate large 
amounts of MS/MS spectra, making exhaustive search for fusion 
protein identification difficult. In this work, a sequence tag-based 
fusion protein identification algorithm, FIT, has been proposed that 
can select fusion partner proteins for more effective fusion peptide 
identification. Filtration of candidate proteins and candidate spec-
tra are two key steps in the FIT algorithm, which significantly 
reduces the number of candidate spectra and candidate fusion part-
ner proteins. To test the method, we relied on real MS/MS spectra 
searched against sequence databases containing simulated protein 
fusion events. In these tests, a relatively high sensitivity of fusion 
protein identification was achieved with low false discovery rate. 
  FIT algorithm (and the entire concept of searching for fusion 
events using proteomic data alone) has several limitations. First, 
FIT has been designed for a particular type of experiments, such as 
IP-MS protein interaction profiling experiments, in which the fu-
sion proteins are expected to be enriched compared to their endog-
enous levels in the cell. For experiments in which the abundance 
level of fusion proteins remains low, filtration of protein sequences 
should be less stringent, and significantly more computational 
resources would then be needed for fusion partner protein selection 
and identification by FIT algorithm. Additionally, the analysis of 
fusion events has been far more successful at the genomic level. 
Databases of known fusion events already exists based on bioin-
formatics analysis of mRNA and EST sequences in the GenBank, 
manual collection of literature data, and integration of other known 
database 34. Furthermore, RNA-seq datasets are now being gener-
ated with increasing frequency, allowing more comprehensive 
analysis of gene fusions and chimera transcripts that previously 
possible. Thus, the search for protein-level evidence of gene fusion 
events would need to be more tightly coupled with the analysis of 
matching transcriptome data generated in parallel with proteomic 
data using matching  biological samples.    
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